EPS for Mustang Bio, Inc. (MBIO) Expected At $-0.25

July 14, 2018 - By Tina Thibodeau

Analysts expect Mustang Bio, Inc. (NASDAQ:MBIO) to report $-0.25 EPS on August, 13.After having $-0.24 EPS previously, Mustang Bio, Inc.’s analysts see 4.17 % EPS growth. The stock increased 0.67% or $0.05 during the last trading session, reaching $7.49. About 86,312 shares traded. Mustang Bio, Inc. (NASDAQ:MBIO) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. The company has market cap of $201.67 million. The Company’s lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. It currently has negative earnings. Mustang Bio, Inc. has a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer; and a license agreement with Harvard University.

More important recent Mustang Bio, Inc. (NASDAQ:MBIO) news were published by: Nasdaq.com which released: “Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes” on June 25, 2018, also Nasdaq.com published article titled: “Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.”, Gurufocus.com published: “Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma” on June 20, 2018. More interesting news about Mustang Bio, Inc. (NASDAQ:MBIO) was released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap” with publication date: June 22, 2018.

Mustang Bio, Inc. (NASDAQ:MBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.